YouTube video by John Noy

In-database healthcare resource utilization (HCRU) extraction across inpatient, emergency, outpatient, pharmacy, and procedure domains for Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) cohorts following DARWIN EU standards.

This study assessed long-term healthcare resource utilization (HCRU) and direct medical costs associated with COVID-19 among adults and children in the United States. Using a large national claims ...

The unprecedented influx of COVID-19 patients during the pandemic has confronted health authorities across multiple countries with severe capacity limits in physical infrastructure and healthcare work...

The use of corticosteroids and increasing duration of corticosteroid use is associated with AEs and HCRU among patients with CSU.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

YouTube video by John Noy

YouTube video by John Noy

YouTube video by Tuga93

Aims This study aims to describe healthcare resource utilization (HCRU) and cost burden associated with COVID-19 cases in Ontario, Canada, and assess variations by vaccination status. Methods We con...

목적: 칼시토닌 유전자 관련 펩타이드를 표적으로 하는 인간화 단일클론항체인 프레마네주맙은 독일과 영국(UK)에서 월 4일 이상 편두통을 겪는 환자에게 승인되었으며, 이전에 4~5회(독일) 또는 3회(영국) 이상의 편두통 예방 치료가 실패한 환자에게 보험 적용이 이루어지고 있다. 본 연구에서는 독일과 영국에서 프레마네주맙 치료를 시작한 환자를 대상으로 실제 임상 효과 및 의료 자원 활용(HCRU)을 평가하였다. 방법: 이 비개입적, 후향적, 의사 패널 기반, 온라인, 다기관 차트 검토 연구에...

YouTube video by John Noy

In this real-world study among patients with obesity and newly diagnosed with OSA, we found that sustained adherence to PAP therapy over 2 years was associated with significantly lower HCRU, including fewer emergency room (ER) visits and hospitalizations, and substantially reduced healthcare costs, compared with patients who did not adhere to PAP therapy. While the per-patient annual savings may be modest at the individual level, ~$600–$700 with equipment in years 1 and 2, respectively, they could translate to substantial cumulative savings at the population level and may represent cost-savings opportunities if the ~80% of OSA patients who remain undiagnosed were treated. For most outcomes, patients with intermediate PAP adherence also demonstrated reductions in HCRU and healthcare costs relative to nonadherent patients, suggesting a dose-dependent relationship. This finding is consistent with previous research indicating measurable clinical and economic benefits even from modest nightly PAP usage (1–3 h of PAP use per night) [37]. The observed decline in PAP adherence over time in the intermediate adherence group underscores the need for targeted interventions, particularly within the first year of treatment, to sustain initial adherence and maximize long-term benefits [38]. Until recently, the impact of untreated or inadequately treated OSA on economic outcomes...

Aim: To compare oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps undergoing functional endoscopic sinus surgery (FE...

A sub-analysis of SPECTRA (Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis) aimed to analyze healthcare resource utilization among 298 critical care patients stratified by the rank of chemotherapy or targeted therapy (C/T) initiation, focusing on 30-day all-cause readmissions, infection-related readmissions, prolonged hospital stays, and median length of hospital stays post-C/T initiation (n=298).MethodsSPECTRA was a multicenter, observational study in patients (≥18 years of age) treated with ≥48 h of C/T in a hospital setting. For HCRU, data were categorized by the rank of C/T initiation: First Rank (N=74), Second Rank (N=70), Third Rank (N=57), Fourth Rank (N=43), Fifth Rank (N=26), and Sixth or more Rank (N=28). The study examined 30-day all-cause readmission rates, 30-day infection-related readmission rates, the number of patients remaining hospitalized 30 days post-C/T initiation, and median hospital length of stay overall and post-C/T initiation for patients discharged within 30 days.Results30-day All-Cause Readmission Rate was 3.4% (variations:1.4% to 4.7% across ranks). 30-day infection-related readmission rate averaged 1.7% overall, (variations: 0% to 3.8%). Patients remaining hospitalized 30 Days after C/T initiation (n=64; 21.5%) were predominantly in the first four ranks. Median hospital length of stay (LOS) was 59.0 days (52.0-72.0). Median Post-C/T LOS for patients discharged within 30 Days was 8.0 days overall, with durations ranging from 4.0 to 12.0 days.ConclusionIn conclusion, the examination of HCRU among critical care patients in the SPECTRA study reveals variations in readmission rates and hospital lengths of stay by the rank of C/T initiation. Further research is warranted to explore factors influencing these variations in HCRU, by novel antibiotics such as C/T. Future research may benefit antimicrobial stewardship and resource management in critical care environments.DisclosuresEmre Yucel, PhD, Merck & Co., Ltd: Stocks/Bonds (Public Company) Jessica Levy, n/a, Merck & Co., Ltd: Stocks/Bonds (Public Company)

Statement of Significance With data from 377 830 patients, increasing PAP usage was associated with a 4.1%–6.2% reduction in HCRU per additional hour of PA